Table 2.
Co-occurring Alzheimer’s disease pathology and clinicopathological correlation, hippocampal neuronal loss, and apolipoprotein E genotype
| Identifier | Montine | Thal | Braak | CERAD | Correlation | Hippocampal neuronal loss | ApoE genotype |
|---|---|---|---|---|---|---|---|
| DR2.3 | A1B1C1 | 2 | 2 | 1 | Low | 2 | Ɛ2/Ɛ3 |
| DR8.1 | A0B1C0 | 0 | 1 | 0 | Not | 2 | Ɛ3/Ɛ3 |
| DR25.1 | A0B1C0 | 0 | 1 | 0 | Not | 1 | Ɛ3/Ɛ3 |
| DR25.5 | A0B1C0 | 0 | 1 | 0 | Not | 2 | Ɛ3/Ɛ3 |
| DR28.1 | A3B1C1 | 5 | 1 | 1 | Low | 0 | Ɛ3/Ɛ4 |
| DR205.1 | A2B1C1 | 3 | 2 | 1 | Low | 1 | Ɛ2/Ɛ4 |
| DR31.1 | A1B1C1 | 2 | 1 | 1 | Low | 1 | Ɛ2/Ɛ3 |
| DR1207.1 | A0B1C0 | 0 | 1 | 0 | Not | 1 | Ɛ3/Ɛ3 |
| DR1213.1 | A0B1C0 | 0 | 1 | 0 | Not | 2 | Ɛ3/Ɛ3 |
ApoE Apolipoprotein E, CERAD Consortium to Establish a Registry for Alzheimer’s Disease
Column 2: Montine classification [39, 83]; column 3: Thal stages for β-amyloid plaques [84]; column 4: Braak stages for neurofibrillary changes [85]; column 5: CERAD stages for senile plaques [86]: 0 = no pathology, 1 = sparse CERAD score; column 6: clinicopathological correlation of Alzheimer’s disease neuropathological changes [39]; column 7: neuronal loss in hippocampal CA1 (scale 0–3): 0 = no pathology, 1 = mild neuronal loss, 2 = moderate neuronal loss; column 8: ApoE genotype